Jeffrey Stavenhagen, Ph.D.

Chief Scientific Officer at Dianthus Therapeutics

Speaker

Dr. Jeffrey Stavenhagen is a recognized expert in early-stage drug development, with 25 years of experience building and leading research teams to advance new therapeutic candidates into clinical development. He is Chief Scientific Officer at Dianthus, where he is responsible for discovery research. He was previously the CSO of Therini Bio and has served in leadership roles at Therachon AG and established Discovery Biologics at Lundbeck A/S. Dr. Stavenhagen began his biotech career as the first employee of MacroGenics, where he built a novel antibody engineering platform that resulted in Margenza^®, one of the first Fc optimized monoclonal antibodies on the market. Throughout his career, he has authored over 40 scientific patents and publications. Dr. Stavenhagen received his Ph.D. in Molecular Biology from Columbia University and performed post-doctoral studies at the Fred Hutchinson Research Center in Seattle.